Filing Flows › Comparisons › ALT vs ALLR
Altimmune vs Allarity Therapeutics: ALT and ALLR compared
Altimmune is the larger company: $26K of revenue in its latest quarter (Q4 2025) against $25K for Allarity Therapeutics (Q1 2026).
Where the money goes: ALT and ALLR
Altimmune (ALT) · Q4 2025
Altimmune, Q4 2025: revenue $26K (+420% year over year), net loss $27.4M, operating cash flow −$19.4M. The chart follows the revenue to costs, profit and cash.
Allarity Therapeutics (ALLR) · Q1 2026
Allarity Therapeutics, Q1 2026: revenue $25K, net loss $2.8M, operating cash flow −$4.5M. The chart follows the revenue to costs, profit and cash.
| Altimmune (ALT) | Allarity Therapeutics (ALLR) | |
|---|---|---|
| Latest quarter | Q4 2025 | Q1 2026 |
| Revenue | $26K | $25K |
| Revenue growth, Y/Y | +420% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$27.4M | −$2.8M |
| Operating cash flow | −$19.4M | −$4.5M |
Questions
Which is bigger, Altimmune or Allarity Therapeutics?
Altimmune is the larger company: $26K of revenue in its latest quarter (Q4 2025) against $25K for Allarity Therapeutics (Q1 2026).
More: Altimmune earnings · how Altimmune makes money · Allarity Therapeutics earnings · how Allarity Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 6, 2026; 10-Q filed May 15, 2026). Fiscal quarters can end on different dates. Not investment advice.